Clinical and Translational Neuroscience Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland; Neuroscience Graduate Program, Brown University, Providence, Rhode Island.
Clinical and Translational Neuroscience Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland.
Biol Psychiatry Cogn Neurosci Neuroimaging. 2023 Jan;8(1):121-128. doi: 10.1016/j.bpsc.2020.12.006. Epub 2021 Mar 9.
The rs1344706 single nucleotide polymorphism in the ZNF804A gene has been associated with risk for psychosis in multiple genome-wide association studies, yet mechanisms underlying this association are not known. Given preclinical work suggesting an impact of ZNF804A on dopamine receptor gene transcription and clinical studies establishing dopaminergic dysfunction in patients with schizophrenia, we hypothesized that the ZNF804A risk single nucleotide polymorphism would be associated with variation in dopamine receptor availability in the human brain.
In this study, 72 healthy individuals genotyped for rs1344706 completed both [F]fallypride and [C]NNC-112 positron emission tomography scans to measure D/D and D receptor availability, respectively. Genetic effects on estimates of binding potential for each ligand were tested first with canonical subject-specific striatal regions of interest analyses, followed by exploratory whole-brain voxelwise analyses to test for more localized striatal signals and for extrastriatal effects.
Region of interest analyses revealed significantly less D/D receptor availability in risk-allele homozygotes (TT) compared with non-risk allele carriers (G-allele carrier group: TG and GG) in the associative striatum and sensorimotor striatum, but no significant differences in striatal D receptor availability.
These data suggest that ZNF804A genotype may be meaningfully linked to dopaminergic function in the human brain. The results also may provide information to guide future studies of ZNF804A-related mechanisms of schizophrenia risk.
在多个全基因组关联研究中,ZNF804A 基因中的 rs1344706 单核苷酸多态性与精神病风险相关,但该关联的机制尚不清楚。鉴于临床前研究表明 ZNF804A 对多巴胺受体基因转录有影响,以及临床研究确定精神分裂症患者存在多巴胺能功能障碍,我们假设 ZNF804A 风险单核苷酸多态性与人类大脑中多巴胺受体可用性的变化有关。
在这项研究中,72 名经 rs1344706 基因分型的健康个体完成了 [F]fallypride 和 [C]NNC-112 正电子发射断层扫描,以分别测量 D/D 和 D 受体的可用性。首先使用经典的基于个体的纹状体感兴趣区分析来测试每种配体结合潜能估计值的遗传效应,然后进行探索性的全脑体素分析,以测试更局部的纹状体信号和纹状体外效应。
感兴趣区分析显示,在关联纹状体和感觉运动纹状体中,风险等位基因纯合子(TT)的 D/D 受体可用性明显低于非风险等位基因携带者(G 等位基因携带者组:TG 和 GG),但纹状体 D 受体可用性无显著差异。
这些数据表明,ZNF804A 基因型可能与人类大脑中的多巴胺能功能有意义地相关。这些结果还可能为未来研究 ZNF804A 与精神分裂症风险相关的机制提供信息。